Clinical Trials Browser

Phase 2 × Interventional × Neurilemmoma × Clear all

Schwannomatosis, Neurilemmoma, Pain, Chronic Pain

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

NCT04163419 2024-03-13

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Phase 2 Unknown

9 enrolled

Schwannomatosis, Neurilemmoma, Hereditary Sensory and Autonomic Neuropathies, Pain

NCT02988726 2017-07-26

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

Phase 2 Terminated

3 enrolled

CNS

Neurilemmoma, Neurofibroma, Central Nervous System Neoplasms

NCT00973739 2016-03-22

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Phase 2 Completed

21 enrolled 8 charts

CNS

Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

Clinical Trials

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors